Phase I/II study of S 49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma multiforme

Trial Profile

Phase I/II study of S 49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma multiforme

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs S-49076 (Primary) ; Bevacizumab
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors IRIS
  • Most Recent Events

    • 06 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 09 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 Preliminary results (n=13) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top